Accessibility Menu
Valneva Se Stock Quote

Valneva Se (NASDAQ: VALN)

$9.80
(-0.7%)
-0.07
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$9.8
Daily Change
(-0.7%) $0.07
Day's Range
$9.65 - $9.96
Previous Close
$9.8
Open
$9.77
Beta
1.10
Volume
53,131
Average Volume
95,823
Market Cap
842M
Market Cap / Employee
$9.80M
52wk Range
$3.62 - $12.25
Revenue
-
Gross Margin
0.55%
Dividend Yield
N/A
EPS
-$0.89
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Valneva Se Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
VALN+64.71%N/AN/A-65%
S&P+14.5%+93.32%+14.09%+59%

Valneva Se Company Info

Valneva SE is a specialty vaccine company. The firm focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. It takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. It operates through the following segments: Commercialized products, COVID, Vaccine candidates and Technologies and services. The Commercialized products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment engages in the development, manufacturing and distribution related to COVID-19 vaccine candidate, VLA2001. The Vaccine candidates segment engages in proprietary research and development programs aiming to generate new approvable products in order to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies, excluding COVID-19 vaccine candidate, VLA2001. The Technologies and services segment provides services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$54.82M33.8%
Gross Profit$27.46M74.8%
Gross Margin50.10%11.8%
Market Cap$482.13M-1.1%
Market Cap / Employee$0.69M0.0%
Employees7000.0%
Net Income-$13.14M51.0%
EBITDA-$8.91M0.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$189.35M34.4%
Accounts Receivable$28.32M-13.4%
Inventory72.538.4%

Liabilities

Q2 2025YOY Change
Long Term Debt$174.03M-13.2%
Short Term Debt$57.13M136.3%

Ratios

Q2 2025YOY Change
Return On Assets-13.74%-7.4%
Return On Invested Capital-28.42%-0.5%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$9.25M79.4%
Operating Free Cash Flow-$7.83M82.8%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book2.021.462.902.432.17%
Price to Sales2.851.942.732.16-27.73%
Price to Tangible Book Value2.381.733.372.833.24%
Enterprise Value to EBITDA-212.19-56.37-
Return on Equity-3.7%-7.6%-43.8%-36.5%103.03%
Total Debt$224.60M$223.99M$228.08M$231.16M2.89%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.